Conexiant
Login
  • JADPRO
  • The ASCO Post
  • JNCCN
JADPRO
  • From the Journal
     
    • Online First

    Issues

    • Current
    • Archive
    • Supplements

    Sections

    • Editorial
    • Research and Scholarship
    • Review Article
    • Grand Rounds
    • Practice Matters
    • Prescriber's Corner
    • Diagnostic Snapshot
    • Meeting Report
    • Meeting Abstracts
  • Topics & Conditions

    Solid Tumors

    • Breast Cancer
    • Central Nervous System Cancers
    • Colorectal Cancer
    • View All

    Hematologic Malignancies

    • Leukemia
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • View All

    Issues in Oncology

    • Cardio-Oncology
    • Genomics/Genetics
    • Clinical Trial Design
    • View All

    Supportive Care

    • Symptom Management
    • Pain Management
    • Palliative Care
    • View All

    Developmental Therapeutics

    • CAR T-Cell Therapy
    • Immunotherapy
    • View All
  • Events

    Live Events

    • JADPRO Live

    Webinars

    • JADPRO Clinical Case Series JADPRO Best Practices Summit

    Coverage

    • Newsreels
    • Meeting Hightlights
  • Education

    Educational Resources

    • Newsreels
    • Expert Conversations
    • FDA Focus
    • Patient Education
    • Roundtable Series
    • Meeting Highlights
    • Resource Centers
  • Multimedia
    • Podcasts
    • Videos
  • About
Subscribe Submission
Submissions Subscribe
JADPRO / Education / FDA Focus / Nubeqa darolutamide for metastatic castration-sensitive prostate cancer

Nubeqa (darolutamide) for metastatic castration-sensitive prostate cancer

June 3, 2025

Initial US Approval:

2019

Key Clinical Studies:

ARANOTE (NCT02799602)

Drug Class/Description:

Androgen receptor inhibitor

Indications and Usage:

NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with:

  • non-metastatic castration-resistant prostate cancer (nmCRPC).
  • metastatic castration-sensitive prostate cancer (mCSPC).
  • metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. 

Dosage and Administration:

Recommended Dosage: NUBEQA 600 mg (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take NUBEQA with food.

For patients with mCSPC treated with NUBEQA in combination with docetaxel, administer the first cycle of docetaxel within 6 weeks after the start of NUBEQA treatment.

Patients should also receive a gonadotropin-releasing hormone (GnRH) agonist or antagonist concurrently or have had bilateral orchiectomy. 

Dosage Forms and Strengths:

Tablets: 300 mg

Contraindications:

None.

Warnings and Precautions:

  • Ischemic Heart Disease: Optimize management of cardiovascular risk factors. Monitor for signs and symptoms of coronary artery disease. Discontinue NUBEQA for Grade 3-4 events. 
  • Seizure: Consider discontinuation of NUBEQA in patients who develop a seizure during treatment.
  • Embryo-Fetal Toxicity: NUBEQA can cause fetal harm and loss of pregnancy. Advise males with female partners of reproductive potential to use effective contraception. 

Adverse Reactions:

In nmCRPC and mCSPC: The most common adverse reactions (>10% with a ≥2% increase over placebo), including laboratory test abnormalities, are increased AST, decreased neutrophil count, increased bilirubin, fatigue, and increased ALT.

In mCSPC in combination with docetaxel: The most common adverse reactions (≥10% with a ≥2% increase over placebo) are constipation, rash, decreased appetite, hemorrhage, increased weight, and hypertension.  The most common laboratory test abnormalities (≥30%) are anemia, hyperglycemia, decreased lymphocyte count, decreased neutrophil count, increased AST, increased ALT, and hypocalcemia. 

Drug Interactions:

  • Combined P-gp and Strong or Moderate CYP3A Inducers: Avoid concomitant use. 
  • Combined P-gp and Strong CYP3A Inhibitors: Monitor patients more frequently for NUBEQA adverse reactions.
  • BCRP Substrates: Avoid concomitant use with drugs that are BCRP substrates where possible. If used together, monitor patients more frequently for adverse reactions and consider dose reduction of the BCRP substrate drug.
  • OATP1B1 and OATP1B3 Substrates: Concomitant use of NUBEQA may increase the plasma concentrations of OATP1B1 or OATP1B3 substrates. If used together, monitor patients more frequently for adverse reactions and consider dose reduction of these drugs. 

Use in Specific Populations:

  • Severe Renal Impairment (not on hemodialysis): Recommended dose is 300 mg twice daily. 
  • Moderate Hepatic Impairment: Recommended dose is 300 mg twice daily.

Adapted From:

https://labeling.bayerhealthcare.com/html/products/pi/Nubeqa_PI.pdf?inline=

 

Every health-care provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications. The provider should always consult the most recent prescribing/product information. FDA Focus information is not guaranteed to be accurate, complete, or current. JADPRO and its editors, authors, reviewers, and commentators cannot be held responsible for any liability incurred as a consequence of the application of any of the information listed within.

More From FDA Focus

Braftovi (encorafenib) with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation

December 20, 2024

Lazcluze (lazertinib) in combination with amivantamab-vmjw for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations

August 19, 2024

Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H or dMMR colorectal cancer

April 08, 2025

Advertisement
Current Issue
May/Jun 2025 Cover
May/Jun 2025 Cover Art
Vol 16 No 3 May/Jun 2025

Rare Diseases and Educational Tools for Advanced Practitioners

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO

May 15, 2025

A Pilot Program Implementing an Evidence-Based Walking Plan to Improve Cancer-Related Fatigue

Jennifer D. Bernt, DNP, FNP-C, AOCNP, Rita Million, PhD, RN, PHNA-BC, CNE, COI, Nicole S. Pham, MPH Et al.

May 15, 2025

Ductal Carcinoma In Situ Non Mass Enhancement on MRI 10 Years Before Mammographic Microcalcifications

Nancy W. Stead, MD, Andria P. Caton, RN, OCN, CHPN

May 15, 2025

Table of Contents Archive
JADPRO Logo
JADPRO's Facebook Account JADPRO's X Account JADPRO's LinkedIn Account
Submissions Subscribe

About

  • About Us
  • Society
  • Terms and Conditions
  • Privacy Policy
  • Advertise With JADPRO

Membership

  • Login

Conexiant Oncology Publications

  • The ASCO Post
  • JNCCN
  • JNCCN 360

Copyright © 2024 Conexiant unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.